D. Leonard

发表

Selective PP2A Enhancement through Biased Heterotrimer Stabilization

M. Galsky, S. Izadmehr, G. Narla, 2020, Cell.

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

A. Gingras, J. Westermarck, A. Difeo, 2019, Oncogene.

Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr307 on PP2Ac.

Dafydd G. Thomas, G. Narla, Sahar Mazhar, 2020, Cell reports.

Inhibitors of farnesyl:protein transferase--a possible cancer chemotherapeutic.

D. Hupe, J. Sebolt-Leopold, J. Scholten, 1996, Bioorganic & medicinal chemistry.

Synergy between Anions and Farnesyldiphosphate Competitive Inhibitors of Farnesyl:Protein Transferase*

D. Hupe, J. Sebolt-Leopold, J. Scholten, 1997, The Journal of Biological Chemistry.

Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21: development of endothelin-B receptor selective antagonists.

A. Sefler, W. L. Cody, D. Leonard, 1995, Journal of medicinal chemistry.

Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.

A. Doherty, D. T. Dudley, W. L. Cody, 1993, Journal of medicinal chemistry.

Pack a STRIPAK with hubs inside a hub

Wei Huang, Derek J. Taylor, D. Leonard, 2021, Nature Structural & Molecular Biology.

Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.

A. Doherty, J. Sebolt-Leopold, J. C. Hodges, 1997, Journal of medicinal chemistry.

The discovery of glycine and related amino acid-based factor Xa inhibitors.

Mostofa A Hena, V. Sahasrabudhe, E. Zhang, 2006, Bioorganic & medicinal chemistry.

Ras farnesyltransferase: a new therapeutic target.

D M Leonard, D. Leonard, 1997, Journal of medicinal chemistry.

Optimization of a Pd-catalyzed intramolecular α-arylation synthesis of tricyclo-[7.3.1.02,7]-trideca-2,4,6-trien-13-ones

N. Powell, R. Kennedy, F. Ciske, 2010 .

M2-like macrophages are responsible for collagen degradation through a mannose receptor–mediated pathway

Sven Burgdorf, David A. Brenner, Roberto Weigert, 2013, The Journal of cell biology.

Structure-activity and biophysical studies of the C-terminal hexapeptide of endothelin

A. Doherty, J. Dunbar, M. Reily, 1995 .

The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis.

A. Difeo, G. Narla, M. Jackson, 2019, Cancer research.

Therapeutic targeting of PP2A.

G. Narla, J. Sangodkar, Caitlin M. O’Connor, 2018, The international journal of biochemistry & cell biology.

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

E. Chen, A. Borczuk, R. Sears, 2017, The Journal of clinical investigation.

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

A. Doherty, D. Mcnamara, E. Dobrusin, 1997, Journal of medicinal chemistry.

RAS FARNESYLTRANSFERASE INHIBITORS

J. Sebolt-Leopold, D. Leonard, 1999 .

Active and passive destabilization of G-quadruplex DNA by the telomere POT1-TPP1 complex.

Derek J. Taylor, A. Axhemi, E. Jankowsky, 2021, Journal of molecular biology.

Multiple and Combinatorial Peptide Synthesis

P. Andrews, T. Sawyer, W. L. Cody, 1994 .

Signalling approaches to inhibition of cellular proliferation

A. Doherty, D. Mcnamara, R. Panek, 2002 .

Design of C-terminal peptide antagonists of endothelin: structure-activity relationships of ET-[16–21, D-His16]

A. Doherty, J. Dunbar, W. L. Cody, 1993 .

Histidylbenzylglycinamides A novel class of farnesyl diphosphate-competitive peptidic farnesyltransferase inhibitors

W. Leopold, D. Leonard, J. Leopold, 2001 .